In its software, Lykos describes MDMA as being a catalyst for the therapeutic approach, which is why it gained so much focus. That isn't anticipated for being as much of a hold-up for other psychedelics, although. “The remainder of us are researching molecules that do not call for precisely the same diploma of therapy,” states Kabir Nath, CEO o